

Application No. 09/923,270
Amendment dated August 29, 2005
Reply to Office Action dated May 3, 2005

Amendments to the Claims:

1-12. (Cancelled)

13. (Currently amended) A nucleic acid sequence comprising an adeno-associated virus (AAV) nucleic acid sequence, wherein said AAV nucleic acid sequence comprises a rep gene or a cap gene or a rep gene and a cap gene, and an AAV helper virus nucleic acid sequence, wherein said AAV helper virus sequence comprises the complete adenovirus 5 sequence with exception of the E1 region.

14. (Previously Presented) A nucleic acid sequence comprising an adeno-associated virus (AAV) nucleic acid sequence and an AAV helper virus nucleic acid sequence, wherein said nucleic acid sequence has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11248.

15. (Currently amended) A nucleic acid sequence comprising an adeno-associated virus (AAV) nucleic acid sequence, wherein said AAV nucleic acid sequence comprises a rep gene or a cap gene or a rep gene and a cap gene, and an AAV helper virus nucleic acid sequence, wherein said AAV helper virus nucleic acid sequence comprises the complete adenovirus 5 sequence with exception of L1 and E1 regions.

16. (Previously Presented) A nucleic acid sequence comprising an adeno-associated virus (AAV) nucleic acid sequence and an AAV helper virus nucleic acid sequence, wherein said nucleic acid sequence has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11817.

17. (Currently amended) A composition comprising a nucleic acid sequence of Claim 13, 14, 15, or 16, and recombinant adeno-associated virus (rAAV) vector.

C:\NrPortb\PALIB\VALT2659960_3.DOC
Attorney Docket No. 31304.704.831

-3-

Application No. 09/923,270
Amendment dated August 29, 2005
Reply to Office Action dated May 3, 2005

18. (Previously Presented) The composition of Claim 17, further comprising a cell.
19. (Previously Presented) The composition of Claim 18, wherein said cell is a mammalian cell.
20. (Currently amended) A method for producing recombinant adeno-associated virus (rAAV) viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to a nucleic acid sequence comprising an AAV nucleic acid sequence, wherein said AAV nucleic acid sequence comprises a rep gene or a cap gene or a rep gene and a cap gene, and an AAV helper virus nucleic acid sequence, wherein said AAV helper virus nucleic acid sequence comprises the complete adenovirus 5 sequence with exception of the E1 region;
 - (b) causing said nucleic acid sequence to enter said cells;
 - [(b)] (c) inducing said cells to develop rAAV viral particles; and
 - [(c)] (d) isolating said rAAV viral particles.
21. (Currently amended) A method for producing recombinant adeno-associated virus (rAAV) viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to a nucleic acid sequence, wherein said nucleic acid sequence has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11248;
 - (b) causing said nucleic acid sequence to enter said cells;
 - [(b)] (c) inducing said cells to develop rAAV viral particles; and
 - [(c)] (d) isolating said rAAV viral particles.
22. (Currently amended) A method for producing recombinant adeno-associated virus (rAAV) viral particle preparation which is not contaminated with helper viruses, comprising:

Application No. 09/923,270
Amendment dated August 29, 2005
Reply to Office Action dated May 3, 2005

a) exposing cells to a nucleic acid sequence comprising an AAV nucleic acid sequence, wherein said AAV nucleic acid sequence comprises a rep gene or a cap gene or a rep gene and a cap gene, and an AAV helper virus nucleic acid sequence, wherein said AAV helper virus nucleic acid sequence comprises the complete adenovirus 5 sequence with exception of L1 and E1 regions;

(b) causing said nucleic acid sequence to enter said cells;

[(b)] (c) inducing said cells to develop rAAV viral particles; and

[(c)] (d) isolating said rAAV viral particles.

23. (Currently amended) A method for producing recombinant adeno-associated virus (rAAV) viral particle preparation which is not contaminated with helper viruses, comprising:

a) exposing cells to a nucleic acid sequence, wherein said nucleic acid sequence has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11817;

(b) causing said nucleic acid sequence to enter said cells;

[(b)] (c) inducing said cells to develop rAAV viral particles; and

[(c)] (d) isolating said rAAV viral particles.

24. (Currently amended) A method for producing recombinant adeno-associated virus (rAAV) viral particle preparation which is not contaminated with helper viruses, comprising:

a) exposing cells to a composition comprising (1) a nucleic acid sequence comprising an AAV virus nucleic acid sequence, wherein said AAV nucleic acid sequence comprises a rep gene or a cap gene or a rep gene and a cap gene, and an AAV helper virus nucleic acid sequence, wherein said AAV helper virus nucleic acid sequence comprises the complete adenovirus 5 sequence with exception of E1 region, and (2) an rAAV vector;

(b) causing said composition to enter said cells;

[(b)] (c) inducing said cells to develop rAAV viral particles; and

Application No. 09/923,270
Amendment dated August 29, 2005
Reply to Office Action dated May 3, 2005

[(c)] (d) isolating said rAAV viral particles.

25. (Currently amended) A method for producing recombinant adeno-associated virus (rAAV) viral particle preparation which is not contaminated with helper viruses, comprising:

a) exposing cells to a composition comprising (1) a nucleic acid sequence, wherein said nucleic acid sequence has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11248 and (2) an rAAV vector;

(b) causing said composition to enter said cells;

[(b)] (c) inducing said cells to develop rAAV viral particles; and

[(c)] (d) isolating said rAAV viral particles.

26. (Currently amended) A method for producing recombinant adeno-associated virus (rAAV) viral particle preparation which is not contaminated with helper viruses, comprising:

a) exposing cells to a composition comprising (1) a nucleic acid sequence comprising an AAV nucleic acid sequence, wherein said AAV nucleic acid sequence comprises a rep gene or a cap gene or a rep gene and a cap gene, and an AAV helper virus nucleic acid sequence, wherein said AAV helper virus nucleic acid sequence comprises the complete adenovirus 5 sequence with exception of L1 and the E1 regions and (2) an rAAV vector;

(b) causing said composition to enter said cells;

[(b)] (c) inducing said cells to develop rAAV viral particles; and

[(c)] (d) isolating said rAAV viral particles.

27. (Currently amended) A method for producing recombinant adeno-associated virus (rAAV) viral particle preparation which is not contaminated with helper viruses, comprising:

a) exposing cells to a composition comprising (1) a nucleic acid sequence, wherein said nucleic acid sequence has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11817 and (2) an rAAV vector;

Application No. 09/923,270
Amendment dated August 29, 2005
Reply to Office Action dated May 3, 2005

(b) causing said composition to enter said cells;

[(b)] (c) inducing said cells to develop rAAV viral particles; and

[(c)] (d) isolating said rAAV viral particles.